Drugs · Brain health technique
Senolytic Combinations
Evidence grade: Experimental
Experimental drug combinations designed to selectively clear senescent (“zombie”) cells that accumulate with age and drive chronic inflammation. Leading examples include dasatinib + quercetin, fisetin, and navitoclax.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Emerging Longevity / Neuroregenerative Agents
- Evidence grade
- Experimental
- Strength of evidence
- Low
How to practice Senolytic Combinations
Not FDA-approved for cognitive or aging use. Human dosing regimens are experimental (e.g., dasatinib 100 mg + quercetin 1,000 mg for 2–3 days monthly). Potential for off-target toxicity and cytopenias. Should only be pursued in formal clinical trials. Long-term cognitive efficacy remains speculative.
The evidence behind Senolytic Combinations
Clearing senescent cells reduces inflammatory signaling (SASP) and may improve tissue regeneration. Animal studies show improved cognition and resilience after senolytic treatment, but human evidence is minimal and mostly short-term safety data. Mechanism: apoptosis of senescent cells reduces systemic inflammation and oxidative stress that accelerate neurodegeneration.
More Drugs techniques
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.